Measuring retinal blood vessel density in patients with microvascular angina
The Value of Measuring Retinal Vascular Density by Optical Coherence Tomography-Angiography (OCT-A) in Patients With Microvascular Angina Confirmed by Myocardial Microcirculatory Resistance Index (MRI).
This study is testing whether a new eye scan can help doctors see if people with microvascular angina have issues with blood flow in their hearts without needing invasive procedures.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 158 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire Dijon Academic / other |
| Locations | 1 site (Dijon) |
| Trial ID | NCT06692751 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of Optical Coherence Tomography-Angiography (OCT-A) to measure retinal vascular density in patients diagnosed with microvascular angina, a condition characterized by impaired blood flow in the heart's microcirculation. The study aims to provide a non-invasive and cost-effective alternative to the invasive measurement of microcirculatory resistance index (MRI) for diagnosing this condition. By correlating retinal microcirculation with cardiac health, the research seeks to enhance diagnostic accuracy and patient management. Participants will undergo blood sampling, ophthalmological examinations, and complete an angina severity questionnaire.
Who should consider this trial
Good fit: Ideal candidates are adults diagnosed with microvascular angina who have undergone an MRI measurement and have no significant coronary artery lesions.
Not a fit: Patients with significant coronary artery lesions, severe retinal pathology, or those unable to provide consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved diagnosis and management of microvascular angina, benefiting millions of patients worldwide.
How similar studies have performed: Previous studies have indicated a correlation between retinal microcirculation and cardiovascular risk, suggesting potential success for this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients managed at Dijon University Hospital, having had an IMR measurement as part of INOCA during a coronary angiographic examination, consecutively includible, without angiographically or functionally significant coronary epicardial lesion (FFR \< 0.80) explaining the clinical picture (= INOCA) * Person having given oral consent * Adult Exclusion Criteria: * Person not affiliated or not benefiting from a social security scheme * Person subject to a legal protection measure (curatorship, guardianship) or a safeguard of justice measure * Pregnant or breast-feeding women * An adult incapable or unable to give consent * Person with macular or retinal pathology, or severe bilateral myopia * Person with genetic or idiopathic cardiomyopathy (dilated, hypertrophic or restrictive cardiomyopathy)
Where this trial is running
Dijon
- CHU Dijon Bourgogne — Dijon, France (Recruiting)
Study contacts
- Study coordinator: Pierre GUILLEMINOT
- Email: pierre.guilleminot@chu-dijon.fr
- Phone: 0380293031
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.